SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology entered amended executive employment agreements with its…

Kura Oncology, Inc. · 8-K filed Jul 29, 2026 at 17:06 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jul 29, 2026 at 17:06 ET

Kura Oncology entered amended executive employment agreements with its CEO, CCO, and COO modifying severance provisions. The changes enhance change-of-control severance benefits (e.g., 24-month salary for CEO in change-of-control termination, full equity acceleration). No departures, appointments, or material financial figures were disclosed.

  • CEO Troy E. Wilson's new agreement provides 12 months base salary severance (non-change-of-control) or 24 months + 200% target bonus (change-of-control).
  • CCO Brian Powl and COO Kathleen Ford each receive 12 months base salary severance (non-change-of-control) or 18 months + 150% target bonus (change-of-control).
  • Change-of-control severance includes full equity acceleration (performance-based awards vest at target) for all three executives.
  • Full copies of the agreements will be filed with the Q3 2026 10-Q.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access